Table 5.

Multivariable Models to Assess H30 and Clinical or Microbiological Persistence as Predictors of Later Adverse Outcomes

			Series 2 Models:a Clinical or Microbiological Persistence			Series 3 Modelsa
	Series 1 Models:a,b H30					H30		Clinical or Microbiological Persistence
Outcome Variable	OR (95% CI)	P Value	Predictor	OR (95% CI)	P Value	OR (95% CI)	P Value	Predictor	OR (95% CI)	P Value
Hospital admission	2.68 (1.35–5.33)	.005	Clinical persist.	2.17 (.89–5.28)	.09	2.56 (1.24–5.26)	.01	Clinical persist.	1.89 (.77–4.69)	.17
			Micro. persist.	1.31 (.47–3.61)	.61	2.68 (1.38–5.45)	.007	Micro. persist.	1.04 (.37–2.97)	.94
New antibiotics	2.04 (1.32–3.16)	.001	Clinical persist.	5.94 (3.40–10.38)	<.001	1.68 (1.06–2.67)	.03	Clinical persist.	5.62 (3.21–9.83)	<.001
			Micro. persist.	5.50 (2.81–10.85)	.001	1.70 (1.07–2.68)	.02	Micro. persist.	5.03 (2.54–9.93)	<.001
New infection	1.73 (1.01–3.00)	.047	Clinical persist.	2.81 (1.59–5.00)	<.001	1.43 (.81–2.53)	.22	Clinical persist.	2.69 (1.51–4.80)	.001
			Micro. persist.	2.95 (1.59–6.45)	<.001	1.39 (.79–2.46)	.25	Micro. persist.	2.75 (1.47–5.16)	.002

Abbreviations: CI, confidence interval; micro., microbiological; OR, odds ratio; persist., persistence.

^a As the main predictor variable(s), series 1 models included H30, series 2 models included clinical or microbiological persistence, and series 3 models included both of these. All models included, in addition to the main predictor variable(s), the following host-related covariates: age, sex, hospital stay in past year, long-term care facility stay in past year, systemic compromise, local compromise, antibiotic use in past 30 days, and hospital (Harborview King County Medical Center, University of Washington Medical Center, or Minneapolis Veterans Affairs Medical Center).

^b Results shown for series 1 models are as shown in Table 3 and Supplementary Table 1.